SPARC slips 10% as USFDA rejects cancer drug application

The company has received a Complete Response Letter (CRL) from the USFDA for the new drug application (NDA) for Taclantis (Paclitaxel Injection Concentrate for Suspension).

from Home Page https://ift.tt/39sYoqF